Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells

Cancer Journal

Volumn 13, Issue 2, 2007, Pages 105-113

  Yu, Xiao Dan ^a   Wang, Sheng Yu ^a   Chen, G Aaron ^b   Hou, Chun Mei ^a   Zhao, Ming ^a   Hong, Julie A ^b   Nguyen, Dao M ^b   Schrump, David S ^b  

^a Institute of Basic Medical Sciences   (China)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Epigenetics; FK228; Lung cancer; Mitogen activated protein kinase

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 5 (2 BENZOTHIAZOLYL)THIOMETHYL 4 HYDROXY 3 METHOXYBENZYLIDENECYANOACETAMIDE; ADENOVIRUS VECTOR; BETA GALACTOSIDASE; BROXURIDINE; DEPSIPEPTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RAF PROTEIN; ROMIDEPSIN; STRESS ACTIVATED PROTEIN KINASE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; BAX PROTEIN, HUMAN; BCL2L1 PROTEIN, HUMAN; CHROMONE DERIVATIVE; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLAVONOID; FR 901228; HISTONE DEACETYLASE; MITOGEN ACTIVATED PROTEIN KINASE; MORPHOLINE DERIVATIVE; PROTEIN BCL X; TYRPHOSTIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG EXPOSURE; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME ASSAY; ENZYME INHIBITION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; NITROBLUE TETRAZOLIUM TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; LUNG TUMOR; METABOLISM; MUTATION; PATHOLOGY;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; CHROMONES; DEPSIPEPTIDES; DOWN-REGULATION; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVONOIDS; HISTONE DEACETYLASES; HUMANS; LUNG NEOPLASMS; MORPHOLINES; MUTATION; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TYRPHOSTINS; UP-REGULATION;

EID: 34347261742     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318046eedc     Document Type: Article

References (43)

1. Feinberg AP. The epigenetics of cancer etiology. Semin Cancer Biol. 2004;14:427-432.
2. Vincenzi B, Schiavon G, Silletta M, et al. Cell cycle alterations and lung cancer. Histol Histopathol. 2006;21:423-435.
3. Yokota J, Kohno T. Molecular footprints of human lung cancer progression. Cancer Sci. 2004;95:197-204.
4. Schrump DS, Nguyen DM. Targeting the epigenome for the treatment and prevention of lung cancer. Semin Oncol. 2005;32:488-502.
5. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell. 2003;4:13-18.
6. Kelly WK, Marks PA. Drug insight: histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hy-droxamic acid. Natl Clin Pract Oncol. 2005;2:150-157.
7. Carey N, La Thangue NB. Histone deacetylase inhibitors: gathering pace. Curr Opin Pharmacol. 2006;6:369-375.
8. Peart MJ, Smyth GK, van Laar RK, et al. Identification and functional significance of genes regulated by structurally different histone deacety-lase inhibitors. Proc Natl Acad Sci U S A. 2005;102:3697-3702.
9. Lin HY, Chen CS, Lin SP, et al. Targeting histone deacetylase in cancer therapy. Med Res Rev. 2006;26:397-413.
10. Brinkmann H, Dahler AL, Popa C, et al. Histone hyperacetylation induced by histone deacetylase inhibitors is not sufficient to cause growth inhibition in human dermal fibroblasts. J Biol Chem. 2001;276: 22491-22499.
11. Yu X, Guo ZS, Marcu MG, et al. Modulation of p53, ErbB1, erbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst. 2002;94:504-513.
12. Bali P, Pranpat M, Swaby R, et al. Activity of suberoylanilide hydrox-amic acid against human breast cancer cells with amplification of her-2. Clin Cancer Res. 2005;11:6382-6389.
13. Fuino L, Bali P, Wittmann S, et al. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther. 2003;2:971-984.
14. Citri A, Yarden Y EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006;7:505-516.
15. Jorissen RN, Walker F, Pouliot N, et al. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res. 2003; 284:31-53.
16. Ogata T, Iijima S, Hoshikawa S, et al. Opposing extracellular signal-regulated kinase and Akt pathways control Schwann cell myelination. J NeuroSci. 2004;24:6724-6732.
17. Amann J, Kalyankrishna S, Massion PP, et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res. 2005;65:226-235.
18. Shimamura T, Lowell AM, Engelman JA, et al. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res. 2005;65:6401-6408.
19. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139.
20. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304:1497-1500.
21. Gollob JA, Wilhelm S, Carter C, et al. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol. 2006;33:392-406.
22. Karin M, Gallagher E. From JNK to pay dirt: jun kinases, their biochemistry, physiology and clinical importance. IUBMB Life. 2005;57: 283-295.
23. Ranganathan AC, Adam AP, Aguirre-Ghiso JA. Opposing roles of mitogenic and stress signaling pathways in the induction of cancer dormancy. Cell Cycle 2006;5:1799-1807.
24. Nguyen DM, Schrump WD, Chen GA, et al. Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clin Cancer Res. 2004;10:1813-1825.
25. Song P, Wei J, Wang HC. Distinct roles of the ERK pathway in modulating apoptosis of Ras-transformed and non-transformed cells induced by anticancer agent FR901228. FEBSLett. 2005;579:90-94.
26. Yu C, Dasmahapatra G, Dent P, et al. Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells. Leukemi.. 2005;19:1579-1589.
27. Rahmani M, Yu C, Reese E, et al. Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21(CIP1/WAF1) induction rather than AKT inhibition. Oncogene. 2003;22:6231-6242.
28. Chinnaiyan P, Varambally S, Tomlins SA, et al. Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition. Int J Cancer. 2006;118:1041-1050.
29. Han JW, Ahn SH, Kim YK, et al. Activation of p21(WAF1/Cip1) transcription through Sp1 sites by histone deacetylase inhibitor apicidin: involvement of protein kinase C. J.Biol.Chem. 2001;276:42084-42090.
30. Gao N, Dai Y, Rahmani M, et al. Contribution of disruption of the nuclear factor-κB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol. Mol Pharmacol. 2004;66:956-963.
31. Liu Y, Denlinger CE, Rundall BK, et al. SAHA induces Akt-mediated phosphorylation of p300 which promotes acetylation and transcriptional activation of RelA/p65. J Biol Chem. 2006;281:31359-31368.
32. Mayo MW, Denlinger CE, Broad RM, et al. Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-κB through the Akt pathway. J Biol Chem. 2003;278: 18980-18989.
33. Weiss RH. p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell. 2003;4:425-429.
34. Rossig L, Badorff C, Holzmann Y, et al. Glycogen synthase kinase-3 couples AKT-dependent signaling to the regulation of p21Cip1 degradation. J Biol Chem. 2002;277:9684-9689.
35. Das D, Pintucci G, Stern A. MAPK-dependent expression of p21(WAF) and p27(kip1) in PMA-induced differentiation of HL60 cells. FEBS Lett. 2000;472:50-52.
36. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97:339-346.
37. Ji H, Li D, Chen L, et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell. 2006;9:485-495.
38. Mukohara T, Engelman JA, Hanna NH, et al. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst. 2005;97: 1185-1194.
39. Sandor V, Bakke S, Robey RW, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res. 2002;8:718-728.
40. Dziadziuszko R, Witta SE, Cappuzzo F, et al. Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer. Clin Cancer Res. 2006;12:3078-3084.
41. Han SW, Hwang PG, Chung DH, et al. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer. Int J Cancer. 2005;113:109-115.
42. Cappuzzo F, Magrini E, Ceresoli GL, et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2004;96:1133-1141.
43. Janmaat ML, Rodriguez JA, Gallegos-Ruiz M, et al. Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. Int J Cancer. 2006;118:209-214.